News of Note—Stent trial controversy, Corindus funding and more

Newspapers
(NS Newsflash/CC BY 2.0)

> Controversy has engulfed a long-running study into the use of stents in patients with stable ischemic heart disease. The row blew up after investigators changed the primary endpoint late in the study. CardioBrief

> Corindus, a provider of robotic-assisted vascular intervention technologies, has put together a $25 million private placement. Statement

> Nexstim has ended negotiations with a potential Chinese distribution partner. The neuromodulation company had hoped to receive a $1.2 million investment through the deal. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.